Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20-17/KM23 trial.

IF 24.9 1区医学 Q1 ONCOLOGY

Cancer Communications Pub Date : 2025-04-11 DOI:10.1002/cac2.70026

Kyoungmin Lee, Kyung-Hun Lee, Dong-Wan Kim, Jeesun Yoon, Yoon Ji Choi, Soohyeon Lee, Ju Won Kim, Kyong Hwa Park, Wonyoung Choi, Youngjoo Lee, Hyewon Ryu, Dong-Hoe Koo, YunGyoo Lee, Hei-Cheul Jeung, Min-Young Lee, Namsu Lee, Myoung Joo Kang, Jieun Lee, Sook Hee Hong, Eun Joo Kang, In Hae Park

引用次数: 0

查看原文本刊更多论文

评估neratinib和曲妥珠单抗生物类似药在HER2突变晚期实体瘤患者中的安全性和有效性的II期研究：KCSG AL20-17/KM23试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Communications Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

25.50

自引率

4.30%

发文量

153

审稿时长

4 weeks

期刊介绍： Cancer Communications is an open access, peer-reviewed online journal that encompasses basic, clinical, and translational cancer research. The journal welcomes submissions concerning clinical trials, epidemiology, molecular and cellular biology, and genetics.